Investment in stem cell rejuvenation startup
The biotech company Mogling Bio completed successfully its first round of seed investments with Kizoo Technology Capital, a single investor.
Mogling Bio develops new pharmacological methods to rejuvenate stem cells in the hematopoietic system (the formation of blood cells).
The increased activity of CDC42 in stem cells causes them to age and lose their normal structure. Normalising CDC42 can restore structure, functionality and order to those aged stem cells.
Source:
